Bionomics is a clinical-stage biopharmaceutical company developing ion channels targeting drug candidates designed for patients suffering from central nervous system (CNS) disorders. The lead clinical candidate is BNC210, a negative allosteric modulator, for the treatment of post-traumatic stress disorder (PTSD), acute social anxiety disorder (SAD), and depression. The company also develops BNC105, a multi-modal small molecule tubulin polymerization inhibitor, and BNC101, a cancer stem cell receptor.